Gsk (GSK) Revenue (2009 - 2026)

Gsk (GSK) has 18 years of Revenue data on file, last reported at $21.5 billion in Q3 2026.

• For the quarter ending Q3 2026, Revenue changed N/A year-over-year to $21.5 billion; the trailing twelve-month figure through Sep 2026 stood at $86.6 billion (changed N/A YoY), and the FY2025 full-year result was $43.5 billion, up 8.34% from the prior year.
• Revenue was $21.5 billion for Q3 2026 at Gsk, up from $11.3 billion in the prior quarter.
• In the past five years, Revenue ranged from a high of $43.5 billion in Q4 2025 to a low of $8.4 billion in Q1 2023.
• A 5-year average of $13.5 billion and a median of $10.3 billion in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue slipped 12.43% in 2023 and soared 122.04% in 2025, its largest moves.
• Gsk's Revenue stood at $16.6 billion in 2022, then grew by 5.89% to $17.5 billion in 2023, then climbed by 11.59% to $19.6 billion in 2024, then surged by 122.04% to $43.5 billion in 2025, then sank by 50.44% to $21.5 billion in 2026.
• Per Business Quant data, the three most recent Revenue figures were $21.5 billion in Q3 2026, $11.3 billion in Q2 2026, and $10.3 billion in Q1 2026.